VALN Valneva SE

Nasdaq valneva.com


$ 10.46 $ -0.09 (-0.86 %)    

Tuesday, 14-Oct-2025 15:59:53 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 10.41
$ 10.21
$ 10.01 x 1
$ 12.30 x 50
$ 10.08 - $ 10.62
$ 3.62 - $ 12.25
74,450
na
1.45B
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for...

 valnevas-ixchiq-shows-95-antibody-seroresponse-sustained-four-years-after-single-dose-in-adults-aged-18-to-65

Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key compe...

 guggenheim-maintains-buy-on-valneva-lowers-price-target-to-13

Guggenheim analyst Vamil Divan maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $14 to $13.

 valneva-lyme-vaccine-candidate-vla15-demonstrates-strong-anamnestic-response-and-favorable-safety-profile-after-third-yearly-booster-dose

Strong immune response after third yearly booster dose in children and adultsSignificant anamnestic antibody response across al...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-18-price-target

HC Wainwright & Co. analyst Brandon Folkes reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $18 price target.

 safety-concerns-hit-valneva-as-ixchiq-chikungunya-virus-vaccine-is-suspended-in-us

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sal...

 fda-update-on-the-safety-of-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety-communication

https://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-bi...

 valneva-announces-fda-suspension-of-ixchiq-license-in-united-states-following-four-new-serious-adverse-events-reports

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the Unit...

 hc-wainwright--co-assumes-valneva-at-buy-announces-price-target-of-18

HC Wainwright & Co. analyst Brandon Folkes assumes Valneva (NASDAQ:VALN) with a Buy rating and announces Price Target of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION